Biosynex (PA:ALBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Biosynex (ALBIO)
Biosynex (PA:ALBIO) has a market capitalization of $15.74 Million (€13.46 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #25945 globally and #425 in its home market, demonstrating a -5.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biosynex's stock price €0.90 by its total outstanding shares 18431912 (18.43 Million). Also see ALBIO asset base for a full breakdown of the balance sheet.
Biosynex Market Cap History: 2015 to 2026
Biosynex's market capitalization history from 2015 to 2026. Data shows change from $53.63 Million to $19.39 Million (-10.14% CAGR). Also see Biosynex cash flow conversion for how efficiently the company converts equity into cash flow.
Biosynex Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biosynex's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Biosynex stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.37x
Biosynex's market cap is 0.37 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $53.63 Million | $10.18 Million | -$364.16K | 5.27x | N/A |
| 2016 | $42.26 Million | $27.14 Million | -$120.09K | 1.56x | N/A |
| 2017 | $63.66 Million | $30.61 Million | $315.22K | 2.08x | 201.94x |
| 2018 | $47.79 Million | $31.30 Million | $542.89K | 1.53x | 88.03x |
| 2019 | $49.70 Million | $34.23 Million | $1.10 Million | 1.45x | 45.26x |
| 2020 | $317.32 Million | $153.90 Million | $31.37 Million | 2.06x | 10.12x |
| 2021 | $507.37 Million | $382.53 Million | $104.00 Million | 1.33x | 4.88x |
| 2022 | $297.37 Million | $196.59 Million | $15.66 Million | 1.51x | 18.99x |
| 2023 | $179.93 Million | $92.98 Million | -$36.95 Million | 1.94x | N/A |
| 2024 | $37.06 Million | $101.20 Million | -$43.30 Million | 0.37x | N/A |
Competitor Companies of ALBIO by Market Capitalization
Companies near Biosynex in the global market cap rankings as of September 20, 2026. Review Biosynex (ALBIO) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Biosynex by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Biosynex Historical Marketcap From 2015 to 2026
Between 2015 and today, Biosynex's market cap moved from $53.63 Million to $ 19.39 Million, with a yearly change of -10.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.39 Million | +51.01% |
| 2025 | €12.84 Million | -65.35% |
| 2024 | €37.06 Million | -79.40% |
| 2023 | €179.93 Million | -39.49% |
| 2022 | €297.37 Million | -41.39% |
| 2021 | €507.37 Million | +59.89% |
| 2020 | €317.32 Million | +538.47% |
| 2019 | €49.70 Million | +4.00% |
| 2018 | €47.79 Million | -24.93% |
| 2017 | €63.66 Million | +50.65% |
| 2016 | €42.26 Million | -21.21% |
| 2015 | €53.63 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Biosynex was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.74 Million USD |
| MoneyControl | $15.74 Million USD |
| MarketWatch | $15.74 Million USD |
| marketcap.company | $15.74 Million USD |
| Reuters | $15.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biosynex
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more